Aurinia Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.92
Dividend & YieldN/A$ (N/A)
Beta 0.92
Market capitalization 703.44M
Operating cash flow -115.9M
ESG Scores unknown

Company description

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -887k 4.01M 13.62M 4.08M
Total Cashflows From Investing Activities -65k 7.78M -158.19M -103.87M
Net Borrowings
Total Cash From Financing Activities 4.01M 243.85M 194.38M 221.11M
Change To Operating Activities -5.11M -1.83M 5.48M -4.65M
Issuance Of Stock 4.01M 257.48M 206.64M 226.73M
Net Income -53.08M -88.39M -102.68M -180.97M
Change In Cash -47.66M 188.05M -33.67M -40.45M
Effect Of Exchange Rate
Total Cash From Operating Activities -51.61M -63.59M -69.86M -157.69M
Depreciation 1.31M 1.17M 1.37M 2.76M
Change To Account Receivables -151k -151k -650k -15.41M
Other Cashflows From Financing Activities -13.63M -13.63M -12.27M -5.62M
Change To Netincome 6.15M 21.6M 26.93M 42.15M
Capital Expenditures -74k -85k -5.58M -297k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 41.38M 52.87M
Income Before Tax -53.01M -88.24M -102.77M -180.21M
Net Income -53.08M -88.39M -102.68M -180.97M
Selling General Administrative 13.69M 22.34M 95.98M 171.44M
Gross Profit -40.92M -52.55M -209k -6.62M
Ebit -55.24M -90.94M -104.29M -180.74M
Operating Income -55.24M -90.94M -104.29M -180.74M
Interest Expense
Income Tax Expense 73k 144k -94k 760k
Total Revenue 463k 318k 50.12M 45.6M
Cost Of Revenue 41.38M 52.87M 50.33M 52.23M
Total Other Income ExpenseNet 2.23M 2.7M 1.52M 529k
Net Income From Continuing Ops -53.08M -88.39M -102.68M -180.97M
Net Income Applicable To Common Shares -53.08M -88.39M -102.68M -180.97M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 33.29M 25.7M 55.91M 64.28M
Total Stockholder Equity 112.58M 298.6M 407.75M 479.09M
Other Current Liabilities 190k 118k 6.41M 4.64M
Total Assets 145.86M 324.3M 463.66M 543.37M
Common Stock 504.65M 746.49M 944.33M 1.18B
Other Current Assets 1.42M 5.82M
Retained Earnings -415.96M -472.48M -575.16M -756.12M
Treasury Stock -805k -805k -805k -852k
Cash 117.97M 306.02M 272.35M 231.64M
Total Current Liabilities 7.26M 11.29M 32M 40.65M
Other Stockholder Equity -805k -805k -805k -852k
Property, Plant, and Equipment 41k 93k 10.28M 9.8M
Total Current Assets 132.85M 315.14M 419.43M 513.32M
Net Tangible Assets 99.96M 289.74M 398.42M 470.69M
Net Receivables 217k 368k 15.41M
Accounts Payable 2.95M 4.15M 2.63M 3.88M


Insider Transactions

Here are the insider transactions of stock shares related to Aurinia Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
DONLEY MATTHEW MAXWELLPurchase at price 4.66 per share.D2022-11-21Officer10k
HABIG SCOTT MICHAELPurchase at price 5.01 per share.D2022-11-09Officer5k
MARTIN MICHAEL ROBERTPurchase at price 5.16 per share.D2022-11-07Officer30k
JAYNE DAVID ROLAND WALKERConversion of Exercise of derivative security at price 3.62 per share.D2022-05-18Director10k
MACKAY-DUNN R HECTORPurchase at price 11.00 per share.D2022-03-09Director5k
MILNE GEORGE M JRPurchase at price 10.82 per share.D2022-03-04Director5k
MILLER JOSEPH MStock Award(Grant) at price 0.00 per share.D2022-03-02Chief Financial Officer8.5k
MILLER JOSEPH MSale at price 12.01 per share.D2022-03-02Chief Financial Officer3.06k
GREENLEAF PETER SStock Award(Grant) at price 0.00 per share.D2022-03-02Chief Executive Officer28.3k
GREENLEAF PETER SSale at price 12.01 per share.D2022-03-02Chief Executive Officer9.07k
DONLEY MATTHEW MAXWELLStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.5k
DONLEY MATTHEW MAXWELLSale at price 12.01 per share.D2022-03-02Officer3.05k
COLAO MASSIMILIANOStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.5k
COLAO MASSIMILIANOSale at price 12.01 per share.D2022-03-02Officer3.21k
SOLOMONS, NEILStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.5k
SOLOMONS, NEILSale at price 12.01 per share.D2022-03-02Officer4.85k
HUIZINGA ROBERT BINDERTStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.5k
HUIZINGA ROBERT BINDERTSale at price 12.01 per share.D2022-03-02Officer4.85k
MARTIN MICHAEL ROBERTStock Award(Grant) at price 0.00 per share.D2022-03-02Officer8.5k
MARTIN MICHAEL ROBERTSale at price 12.01 per share.D2022-03-02Officer4.85k
ROBERTSON STEPHEN PStock Award(Grant) at price 0.00 per share.D2022-03-02General Counsel8.5k
HAGAN JOSEPH PATRICKSale at price 22.58 - 23.29 per share.D2022-01-03Director40k
HAGAN JOSEPH PATRICKConversion of Exercise of derivative security at price 5.08 per share.D2022-01-03Director40k
LEVERSAGE JILL DIANEPurchase at price 20.04 per share.D2021-12-13Director1.6k
SOLOMONS, NEILSale at price 28.89 - 31.17 per share.D2021-11-11Officer250k
SOLOMONS, NEILConversion of Exercise of derivative security at price 5.30 - 6.06 per share.D2021-11-11Officer200k
MARTIN MICHAEL ROBERTSale at price 28.82 - 31.26 per share.D2021-11-11Officer150k
MARTIN MICHAEL ROBERTConversion of Exercise of derivative security at price 18.38 per share.D2021-11-11Officer29k
SOLOMONS, NEILSale at price 31.64 per share.D2021-11-01Officer45k
SOLOMONS, NEILConversion of Exercise of derivative security at price 5.30 per share.D2021-11-01Officer45k
MARTIN MICHAEL ROBERTSale at price 31.64 per share.D2021-11-01Officer45k
MARTIN MICHAEL ROBERTConversion of Exercise of derivative security at price 3.20 per share.D2021-11-01Officer45k
HUIZINGA ROBERT BINDERTSale at price 29.75 per share.D2021-10-25Officer130k
HUIZINGA ROBERT BINDERTConversion of Exercise of derivative security at price 3.20 per share.D2021-10-25Officer95k
HUIZINGA ROBERT BINDERTSale at price 23.66 - 24.05 per share.D2021-09-21Officer32.5k
HUIZINGA ROBERT BINDERTConversion of Exercise of derivative security at price 2.63 - 3.20 per share.D2021-09-21Officer27.14k
MARTIN MICHAEL ROBERTSale at price 21.60 - 24.02 per share.D2021-09-21Officer116k
MARTIN MICHAEL ROBERTConversion of Exercise of derivative security at price 5.30 - 18.38 per share.D2021-09-21Officer116k
HUIZINGA ROBERT BINDERTSale at price 19.76 - 21.75 per share.D2021-09-14Officer32.5k
MARTIN MICHAEL ROBERTSale at price 19.80 - 21.19 per share.D2021-09-14Officer115k
MARTIN MICHAEL ROBERTConversion of Exercise of derivative security at price 3.20 - 5.30 per share.D2021-09-14Officer115k
MARTIN MICHAEL ROBERTSale at price 21.73 - 21.80 per share.D2021-09-14Officer44k
MARTIN MICHAEL ROBERTConversion of Exercise of derivative security at price 5.30 per share.D2021-09-14Officer44k
SOLOMONS, NEILConversion of Exercise of derivative security at price 3.20 per share.D2021-09-13Officer150k
SOLOMONS, NEILSale at price 19.84 per share.D2021-09-10Officer150k
HUIZINGA ROBERT BINDERTSale at price 18.30 per share.D2021-09-07Officer5k
MARTIN MICHAEL ROBERTSale at price 18.10 per share.D2021-09-07Officer7.5k
MARTIN MICHAEL ROBERTSale at price 17.81 per share.D2021-08-26Officer22.5k
SOLOMONS, NEILSale at price 15.85 per share.D2021-08-25Officer5k
SOLOMONS, NEILSale at price 16.03 per share.D2021-08-09Officer45k
MARTIN MICHAEL ROBERTSale at price 16.01 per share.D2021-08-09Officer5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Aurinia Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Aurinia Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Aurinia Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Aurinia Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Aurinia Pharmaceuticals Inc:

Aurinia Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 283.95% on the backtest period.

Performance at glance

Performance

283.95 %

Latent gain

4990.32 $

Invested capital

1757.46 $

Annualized return

69.26 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Aurinia Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Aurinia Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Aurinia Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Aurinia Pharmaceuticals Inc:

Aurinia Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 340.76% of return on Aurinia Pharmaceuticals Inc. That represents 19606.45$ of latent gain with 5753.69$ of employed capital.
  • The second momentum investment strategy would give 326.14% of return on Aurinia Pharmaceuticals Inc. That represents 20363.58$ of latent gain with 6243.78$ of employed capital.
Performance at glance (1Q Momentum)

Performance

340.76 %

Latent gain

19606.45 $

Invested capital

5753.69 $

Annualized return

39.4 %
Performance at glance (2Q Momentum)

Performance

326.14 %

Latent gain

20363.58 $

Invested capital

6243.78 $

Annualized return

90.09 %

Momentum equity curve on Aurinia Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Aurinia Pharmaceuticals Inc:

Aurinia Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Aurinia Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Aurinia Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Aurinia Pharmaceuticals Inc since the beginning:

Aurinia Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Aurinia Pharmaceuticals Inc

Buy the dip entry openings on Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

The performance achieved by the robo-advisor on Aurinia Pharmaceuticals Inc is 82.74%. That represents 202.72$ of latent gain with 245.0$ of employed capital. The following chart shows Aurinia Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Aurinia Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

82.74 %

Latent gain

202.72 $

Invested capital

245.0 $

Annualized return

39.4 %

Equity curve of the strategy applied to Aurinia Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Aurinia Pharmaceuticals Inc:

Aurinia Pharmaceuticals Inc

Note: the dividends potentially given by Aurinia Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Aurinia Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Aurinia Pharmaceuticals Inc:

Aurinia Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Aurinia Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Aurinia Pharmaceuticals Inc.

Equity curve comparison on Aurinia Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Aurinia Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc investment comparison

Performance comparison on Aurinia Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 283.95% 4990.32$ 1757.46$ 69.26%
Momentum 1 quarter 340.76% 19606.45$ 5753.69$ 88.28%
Momentum 2 quarters 326.14% 20363.58$ 6243.78$ 90.09%
Non-directional 82.74% 202.72$ 245.0$ 39.4%
Annualized return comparison

Automatic investment

69.26 %

Momentum 1Q

90.09 %

Momentum 2Q

90.09 %

Non-directional

39.4 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Aurinia Pharmaceuticals Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • CHINA TOUYUN

  • Note: The algorithm computes the probability of correlation between Aurinia Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Aurinia Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Aurinia Pharmaceuticals Inc
    Country Canada
    City Victoria
    Address 4464 Markham Street
    Phone
    Website www.auriniapharma.com
    FullTime employees 300
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker AUPH
    Market www.nasdaq.com

    Aurinia Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown